CYP1B1 Gene Glaucoma (Primary Type 3A) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines

تحليل جين CYP1B1 لمرض الزرق الأولي من النوع 3A في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

Executive Summary

تقدم هذه الخدمة تحليلاً جينياً فائق الدقة لجين CYP1B1 للكشف المبكر عن الزرق الخلقي الأولي من النوع 3A وفق أعلى معايير الجودة العالمية.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Sequencing.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy (8 AM–11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with a DHA-licensed genetic counselor.
Insurance & Billing: Direct Billing Verification via WhatsApp at +971 54 548 8731.

Clinical Test Overview

The CYP1B1 gene test detects sequence variants causing primary congenital glaucoma type 3A – a severe, early-onset eye disorder. This test empowers families with genetic clarity, enabling early intervention and sight preservation while meeting all UAE genetic screening mandates.

Feature	Our Test (Premium NGS)	Standard Genetic Panels
Precision	Full gene sequencing with CNV detection; 99.9% analytical sensitivity	Targeted genotyping only; limited to common mutations
Methodology	Next‑Generation Sequencing (NGS) confirmed by Sanger sequencing	Microarray or single‑site PCR
TAT	3–4 weeks with rapid genetic counselling option	4–6 weeks; no counselling included

Physician Insight & Safety Protocol

“This test uncovers the genetic blueprint of primary congenital glaucoma; a negative result does not rule out non‑CYP1B1 glaucomas, so comprehensive ophthalmic follow‑up remains essential. We interpret every variant through the lens of your family’s unique medical journey to guide precise, life‑long eye care.”

— Dr. PRABHAKAR REDDY, DHA License No. 61713011

⚠️ Medication Warning:

Do not discontinue or adjust any prescribed eye drops, oral medications, or ongoing therapies without consulting your treating physician. Genetic testing is a diagnostic aid, not a replacement for clinical management.

🚨Safety & Exclusion Criteria

Exclusion criteria: Active systemic infection, recent blood transfusion (<4 weeks), or inability to provide informed consent (legal guardian required for minors).
Sample requirements: 2–5 mL whole blood in EDTA, extracted DNA, or one drop of blood on an FTA card; must be collected under cold-chain protocol if outside lab.
Emergency red flags: Acute vision loss, severe eye pain, corneal clouding, or sudden eye pressure rise – proceed to the nearest ophthalmology ER immediately. Genetic results will not alter emergent management.

Patient FAQ & Clinical Guidance

1. What does a positive CYP1B1 test mean for my child’s vision?

Snippet Answer: A positive result confirms a pathogenic variant linked to primary congenital glaucoma type 3A, guiding immediate surgical or laser intervention to prevent irreversible optic nerve damage and preserve sight.

The result provides a definitive molecular diagnosis, allowing your paediatric ophthalmologist to tailor treatment and family surveillance with precision. Genetic counselling will explain inheritance risks for future children.

٢. هل يمكن إجراء الاختبار لحديثي الولادة في الإمارات؟

Snippet Answer: نعم، يُجرى الاختبار لحديثي الولادة بشرط موافقة الوالدين القانونية، ويستخدم تحليل الحمض النووي من عينة دم صغيرة أو بطاقة FTA للحصول على تشخيص مبكر خلال ٣-٤ أسابيع.

يُوصى بالاختبار عند الاشتباه السريري بالزرق الخلقي أو في حال وجود تاريخ عائلي مؤكد، مع ضرورة الاستشارة الوراثية قبل الولادة أو بعدها لتفسير النتائج بدقة.

3. Is the home collection service HIPAA/GDPR/UAE PDPL compliant and how does it work?

Snippet Answer: Yes, our ISO-certified home collection uses encrypted digital consent, a trained phlebotomist with a temperature‑monitored cold chain, and anonymized sample tracking to fully comply with UAE PDPL and Federal Decree‑Law No. 41 of 2024.

Schedule your visit via WhatsApp; we arrive at your doorstep, verify identity, and transport the sample to our DHA‑licensed facility within 2 hours. All genetic data is stored on servers within the UAE with strict access controls.

🔬 Regulatory Compliance & Accreditations

Licensed by Dubai Health Authority (DHA) – Facility License No. 9834453
Certified to ISO 9001:2015 (Certificate No. INT/EGQ/2509DA/3139)
adheres to Federal Decree-Law No. 41 of 2024 (Article 87) on genetic screening and the CDS Law 2026 for minors – mandatory genetic counselling and parental consent.
Data privacy safeguarded under UAE Personal Data Protection Law (PDPL); all samples and reports processed solely within UAE borders.
Methods: Next‑Generation Sequencing (NGS) with Sanger confirmation; Methodology code: LOINC 82802-1
Top ICD-10-CM 2026 Assignments: Q15.0 (Congenital glaucoma), Z13.5 (Encounter for screening for eye and ear disorders), Z84.89 (Family history of other specified conditions)